Effect of anti-IL-1[beta] antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial

Aims Evaluate anti-interleukin-1[beta] (IL-1[beta]) antibody, canakinumab, in patients with type 2 diabetes and impaired glucose tolerance (IGT) in whom hyperglycaemia may trigger IL-1[beta]-associated inflammation leading to suppressed insulin secretion and [beta]-cell dysfunction. Methods This 4-w...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2012-12, Vol.14 (12), p.1088
Hauptverfasser:	Rissanen, A, Howard, C P, Botha, J, Thuren, T
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!